- Mon - Fri: 9:00 am - 5:00 pm
Why TM Flow is important in modern healthcare? Diseases like diabetes, hypertension, cardiovascular events, and peripheral arterial diseases are chronic and it accounts for more than 70% of global deaths. This estimate is provided by World Health Organization. One of the great challenges the clinicians face is to detect these vascular and autonomic dysfunction in the early stages because these dysfunctions develop over years silently without any symptoms.
LD Technology, a company which has patented its pathbreaking TM Flow medical diagnostic platform, which has transformed the early detection in many ways. TM Flow is fast, non-invasive, and a complete vascular and autonomic screening, which helps clinicians to detect the risk of vascular and autonomic diseases before it becomes irreversible.
What is TM Flow?
There are three advanced diagnostic techniques right now available. TMFlow combines all the three into a single system which delivers clinical-grade accurate result in just under 10 minutes’ time. It is an ideal platform for cardiology, primary care, neurology, diabetology, and preventive medicine practices.
TMFlow is nothing but a non-invasive platform which is designed to provide assessment of vascular function, autonomous nervous system functions, pseudo motor functions assessment in a non-invasive manner.
The three FDA-approved diagnostic technologies are
TBL-ABI, which is known as ankle brachial index, which measures the ABI and the volume plethysmography.
Sweat C is another diagnostic technology which measures Galvanic skin responses to assess the sweat gland function. The sweat gland is otherwise called a sudomotor.
The third technology is OXIW, which is a photoplethysmography, PPG, to analyze the variability in heart rate and endothelial functions.
All these data are processed by the Flow7 software and CCS cloud, which enables secured reporting, interpretation, and collaboration by the medical personnel.
TM flow is important Clinically.
Early detection – you have to detect the chronic diseases earlier so that you can reverse and make course correction. As per the recent research, the autonomic dysfunction often leads to diabetes and cardiovascular disease in 5 to 10 years. Also, the endothelial dysfunction is one of the markers which detects earlier, the onset of atherosclerosis.
TM flow enables the detection of PAD, the peripheral arterial disease, small fiber neuropathy, cardiac autonomic neuropathy, CAN, microvascular dysfunction, and the risk of cardiometabolic activities. If you have any findings, you can change your lifestyle habits and intervene with therapeutic process to make sure the long-term outcomes could be improved significantly.
One test, Multiple insights on diagnosis:
The old traditional diagnosis needs different instruments, multiple specialists, and appointments to find out what is wrong. But TM flow is one platform where it consolidates vascular, autonomic, pseudo-motor, and endothelial causes.
The vascular measurement is about ABI, volume plethysmography, and arterial stiffness. The autonomic takes care of HRV and cardiac autonomic reflex test. Pseudo-motor is about sweat gland function and endothelial talks about microvascular PPG analysis. This makes TM flow the real one-stop vascular and autonomic platform for screening.
Step-by-step screening process of TMT flow.
Step 1: Measurement of ABI, known as vascular screening.
The oscillometric pressure cuffs are placed on the arms and ankles to calculate the ankle-brachial index, which is commonly called as ABI. ABI has a formula where ABI = ankle systolic pressure / brachial systolic pressure. The normal ABI reading should be 1.0 to 1.4. If there is a PAD, then the mark should be less than 0.9. This test is primarily used to find PAD and blockages in arteries, even in asymptomatic patients.
Step 2: Testing the Sudomotor function:
Sudomotor function testing is also known as neuropathy screening. Using the galvanic skin responses, the TMFlow platform checks the sweat gland activity, which reflects the health of the small fiber nerve. The Sudomotor dysfunction is one of the early signs of diabetic neuropathy. Many clinical studies have substantiated that. This normally happens several years before the onset of diabetic neuropathy.
Step 3: Autonomic testing:
The ANS assessment is the other name of autonomic testing. The TEM flow platform helps to analyze the heart rate variability, HRV, and Ewing test, which is done for cardiac autonomic reflex testing. This is performed by evaluating the deep breathing, changes in postures & Valsalva maneuvers. The sympathetic and parasympathetic balance can be assessed by these tests, which is very important to diagnose the orthostatic hypotension, arrhythmia risk, sudden cardiac event and cardiac autonomic neuropathy.
Important clinical applications of TM flow:
Metabolic disorders and diabetes.
It helps in early detection of diabetic neuropathy. Microvascular diseases can be identified and cardio-metabolic risk stratification can also be found out. The clinical validation shows there is a high correlation between TM flow readings and glucose tolerance testing test readings (OGTT).
Cardiology:
TM Flow detects the autonomic imbalance and screens the endothelial dysfunction. Arterial stiffness also measured. These three important findings are strong predictors of cardiac mortality and coronary arterial disease.
Neurology:
TM Flow detects small fiber neuropathy in the early stages. They can differentiate vascular and neuropathic pain. TM Flow assists the physicians to identify what are the root causes of chronic lower limb pain so that wrong diagnosis can be avoided.
preventive and primary care:
Annual screening is important for wellness. The risk stratification and lifestyle intervention and monitoring is important care to be taken after we find the risks of events in future. TMFlow is a key platform where it monitors the improvement of treatments and lifestyle changes and have historical data to validate it.
clinical accuracy:
We have validated TM flow’s performance and accuracy across published clinical studies. We have gone through 11+ clinical studies which shows the ABI has a sensitivity of 77.8% and specificity of 77.8%. The TBI sensitivity is 100% and specificity is 55.6%. PTG index and combined vascular score has a sensitivity of 100% whereas the specificity lies like 83.3 and 88.9%. These results shows the high reliability of TM flow which is compared to traditional Doppler ultrasound scans in vascular screening.
The business and practice benefits of using TMFlow.
The ecosystem of TMFlow Diagnostics is as follows.
The TMFlow goes to Flow7, and the data is stored in CCS Cloud, where a specialist is assigned to this particular diagnosis, and the physician is involved and makes the final findings and posits to the patient. This ecosystem helps the process by providing faster diagnosis, and accuracy of the data is much better. The operational burden is reduced, and the outcomes on the patient’s health always improved.
Preventive diagnostics future:
The whole healthcare is moving from reactive treatment to preventive action. TMFlow is the feature of prevention. It is right there in the middle by providing detection of early diseases, stratification of risks, precision-guided therapy, and continuous monitoring of patients will be by combining the three process of vascular, autonomic testing and cloud-based analytics. TMFlow is right now the most comprehensive diagnostic platforms for cardio metabolic disorders.
Finally, TMFlow is just not a device to diagnosis, but it is a complete clinical intelligence system to find the onset of chronic diseases much earlier. The healthcare centers, like clinics, diagnostic centers, and hospitals, who all thrive to deliver future-ready healthcare, TMFlow is the need of the hour. TMFlow takes care of clinical accuracy, optimization of revenue, operational efficiency, and excellent patient care.
